Boehringer Ingelheim

CHMP Issues Positive Opinion to Expand Labeling of Jardiance, Synjardy and Glyxambi to Include Positive Effects on Cardiovascular and Renal Outcomes
CP Wire
Mon, 07/2/18 - 10:02 am
CHMP
Boehringer Ingelheim
Eli Lilly
EMA
Jardiance
Synjardy
Glyxambi
diabetes
CHMP Issues Positive Opinion to Expand Labeling of Jardiance, Synjardy and Glyxambi to Include Positive Effects on Cardiovascular and Renal Outcomes
Mon, 07/2/18 - 09:26 am
Boehringer Ingelheim
Eli Lilly
Jardiance
Synjardy
Glyxambi
ADA: Lilly, BI's Jardiance cut kidney disease progression in Empa-Reg analysis
Fierce Pharma
Mon, 06/25/18 - 09:06 pm
ADA
kidney disease
Eli Lilly
Boehringer Ingelheim
5 Biggest Blockbuster Diabetes Drugs of the Future
Motley Fool
Sun, 06/24/18 - 10:04 am
Eli Lilly
Trulicity
Novo Nordisk
Ozempic
Boehringer Ingelheim
Jardiance
Tresiba
NovoRapid
Boehringer backs €20B R&D game plan with a $272M blueprint for new facility — 100 new hires
Endpoints
Fri, 06/22/18 - 10:23 am
Boehringer Ingelheim
R&D
Germany
Two drugs in the pipeline representing unique marketing challenges
Medical Marketing and Media
Tue, 06/5/18 - 10:37 pm
valrox
Biomarin
hepatitis A
risankizumab
AbbVie
Boehringer Ingelheim
psoriasis
Reversal Agent for Pradaxa, Praxbind, Now Available Nationwide
CP Wire
Fri, 05/4/18 - 06:48 pm
Boehringer Ingelheim
Pradaxa
Praxbind
Reversal Agent for Pradaxa, Praxbind, Now Available Nationwide
Fri, 05/4/18 - 10:22 am
Boehringer Ingelheim
Pradaxa
Praxbind
Pharma's social media strategies are growing up—and working better, too, report finds
Fierce Pharma
Mon, 03/26/18 - 09:34 am
social media
Novo Nordisk
JNJ
Novartis
Boehringer Ingelheim
Lilly, Boehringer add two Jardiance heart failure studies to examine effects on exercise
Fierce Pharma
Wed, 03/7/18 - 12:00 pm
Eli Lilly
Boehringer Ingelheim
Jardiance
heart failure
exercise
diabetes
Boehringer ends Alzheimer's research for PDE9 blocker
Biopharma Dive
Sat, 02/10/18 - 09:22 am
Boehringer Ingelheim
Alzheimer's disease
PDE9 blockers
BI 409306
Boehringer strikes Jardiance outcomes deal with Prime PBM
Biopharma Dive
Thu, 02/1/18 - 09:55 am
Boehringer Ingelheim
Jardiance
PBMs
diabetes
Prime Therapeutics
outcomes-based contracts
Boehringer Ingelheim inks outcomes-based contract with pharmacy benefit manager for diabetes drug
Drug Delivery Business News
Mon, 01/29/18 - 03:20 pm
Boehringer Ingelheim
PBMs
outcomes-based contracts
diabetes
Jardiance
Prime Therapeutics
Boehringer, hot on deals, adds another with Adimab collaboration
Biopharma Dive
Fri, 01/12/18 - 06:29 pm
Boehringer Ingelheim
Adimab
drug discovery
Boehringer, BeiGene enter manufacturing pact for PD-1 drug
Biopharma Dive
Thu, 01/11/18 - 11:54 pm
Boehringer Ingelheim
BeiGene
tislelizumab
anti-PD-L1
drug manufacturing
All in: Boehringer Ingelheim more than doubles its venture fund to €250M
Endpoints
Thu, 01/4/18 - 10:12 pm
venture capital
Boehringer Ingelheim
Boehringer Ingelheim inks CNS deal with Autifony
BioPharma Dive
Tue, 12/19/17 - 11:59 am
Boehringer Ingelheim
Autifony
CNS
Boehringer Ingelheim loses CFO due to disagreement on group’s strategy
GoinPharma
Sun, 12/17/17 - 11:30 am
Boehringer Ingelheim
J&J, Lilly and AZ diabetes medications get another helping of real-world heart benefits
Fierce Pharma
Fri, 11/24/17 - 09:23 am
JNJ
Eli Lilly
AstraZeneca
Boehringer Ingelheim
diabetes
Invokana
Farxiga
Jardiance
Boehringer Ingelheim denies rumors on acquisition of Korea’s CJ Healthcare ($896m)
GoinPharma
Fri, 11/17/17 - 10:22 am
Boehringer Ingelheim
Korea
CJ Healthcare
M&A

Pages